Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

The study will look at how repeatable the NaF PET scans are before treatment. Scans will also
be performed after standard chemotherapy or hormone-directed treatment. This will allow
evaluation of how the NaF PET scans change with the chemotherapy or hormone-directed therapy.
In addition, NaF PET scans will be compared with standard computed tomography (CT) and bone
scans, as well as prostate specific antigen (PSA). This information could be used to develop
better ways to measure prostate cancer bone lesions. In turn, this could be used to better
evaluate treatment effects of standard chemotherapy and other new drugs being developed to
treat prostate cancer.

Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the prostate

- Identifiable prostate cancer-related bone metastases on bone scan in the spine, pelvis
or other bone

- Patients must be starting a microtubule directed chemotherapy regimen for metastatic
castrate-resistant prostate cancer OR

- Patients must be starting a AR-directed regimen (e.g. Abiraterone, MDV-3100, TAK-700,
etc) for treatment of metastatic castrate-resistant prostate

Exclusion Criteria:

- Concurrent treatment with any other agent that is being used with the expressed
purpose of treating of prostate cancer outside of the planned treatment regimen

- Patients who have received radiotherapy less than 4 weeks prior to registration.

- Patients who have received prior Strontium-89, Samarium-153, or other radioisotope.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to sodium fluoride F-18 (NaF).